- Home
- INVA vs ZYME Comparison
INVA vs ZYME Comparison
Compare INVA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | ZYME |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INVA | ZYME |
|---|---|---|
| Price | $23.32 | $25.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $32.80 | ★ $38.90 |
| AVG Volume (30 Days) | 541.3K | ★ 580.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | 33.33 |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $217,217,000.00 | $105,965,000.00 |
| Revenue This Year | $8.95 | $162.82 |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | $6.98 | ★ N/A |
| Revenue Growth | ★ 62.63 | 38.87 |
| 52 Week Low | $16.52 | $9.03 |
| 52 Week High | $25.15 | $28.49 |
Technical Indicators
Market Signals| Indicator | INVA | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 61.50 |
| Support Level | $20.56 | $22.28 |
| Resistance Level | $25.15 | $26.94 |
| Average True Range (ATR) | 0.53 | 0.91 |
| MACD | 0.09 | 0.20 |
| Stochastic Oscillator | 88.04 | 77.42 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.